Direct-acting antiviral drugs like sofosbuvir have provided amazing (albeit very expensive) outcomes in patients with hepatitis C (HCV), with cure rates approaching 90 percent. Can these medications—which promise a rapid cure of HCV, as opposed to long-term management of the virus and its complications—do the same for children?
The answer is, we don’t yet know. We need to figure it out quickly, though, because as Gastroenterology & Endoscopy News (G&EN) reports, doctors are seeing a surge of HCV cases associated with injection drug use among adolescents and young adults.
But we may have more information soon. Maureen Jonas, MD, clinical director of the Center for Childhood Liver Disease at Boston Children’s Hospital, tells G&EN that pediatric studies of these drugs are ongoing. …Read More